Formycon and Bioeq Report Submission of BLA to the US FDA for FYB201 (biosimilar, ranibizumab)

 Formycon and Bioeq Report Submission of BLA to the US FDA for FYB201 (biosimilar, ranibizumab)

Shots:

  • Formycon and partner Bioeq have submitted a BLA for FYB201 (biosimilar referencing Lucentis) to the FDA
  • Lucentis is a mAb fragment used to treat various types of macular-degenerative diseases and other serious eye diseases. If approved, Coherus will commercialize FYB201 in the US
  • Currently, Formycon has four biosimilars while Coherus also has a biosimilar bevacizumab CHS-305 which is currently under development in collaboration with Innovent

Click here to­ read full press release/ article | Ref: Formycon | Image: Formycon

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post